Connect with us

Research Reports

The Global Biological Drugs Market To Be Driven By The Non-Stoical Approach

The Spirulina Extract Market’S Growth Is To Be Defined By Innovation Continuously

 

According to a new market report published by Persistence Market Research “Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020”, the global biological drugs market was valued at US$ 161,056.5 Mn in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach US$ 287,139.7 Mn by 2020.

Biological drugs are typically derived from living cells and are used in the prevention and treatment of various diseases such as cancer, blood disorders, auto-immune diseases, and other medical disorders. Biological drugs have more complex structures compared to that of conventional drugs.

Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/2883

Some of the major players in the biological drugs market:

  • Pfizer Inc.
  • Abbott Laboratories.
  • Novartis AG.
  • Eli Lilly and Company.
  • GlaxoSmithKline plc.
  • Bristol-Myers Squibb Company.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Baxter International Inc.
  • Biogen Idec.

Globally, the biological drugs market is witnessing significant growth due to the increasing prevalence of chronic diseases and growing geriatric population. In addition, health and awareness initiatives by various government associations are also supporting the growth of the biological drugs market. However, high costs of biological drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, risks of adverse effects associated with biologic injectable drugs also inhibit the growth of the market.

Request for Methodology@ https://www.persistencemarketresearch.com/methodology/2883

North America dominates the global biological drugs market. This is due to increasing use of biological drugs in the treatment of diseases such as cancer, diabetes, and other chronic diseases in the region. In addition, several clinics in the region are focusing on biological drugs for the treatment of various diseases.

The biological drugs market in Europe is growing due to increasing aging population in the region. For instance, according to a UN report, elderly people accounted for 23.2% of the total population in Germany in 2000, and the number is expected to reach 33.2% by 2025. Aging can lead to certain disorders such as age-related macular degeneration and glaucoma, which require effective biological drugs for their treatment.

Low manufacturing costs in Asia are attracting biopharmaceutical companies to invest in the region, supporting the growth of the biological drugs market. Moreover, governments of some Asian countries are also supporting the growth of the biological drugs market by providing funds to life sciences research institutes and biotech companies for the construction of R&D and manufacturing facilities.

Access Full Report@ https://www.persistencemarketresearch.com/checkout/2883

The global biological drugs market is segmented as follows:

By therapeutic protein

  • Enbrel
  • Lantus
  • Neulasta
  • Avonex
  • NovoLog
  • Rebif
  • Humalog
  • Aranesp
  • Epogen
  • Levemir
  • Victoza
  • Betaseron
  • Neupogen
  • Eylea

By monoclonal antibody (mAb)

  • Humira
  • Remicade
  • Rituxan
  • Avastin
  • Herceptin
  • Lucentis

By vaccine

  • Prenvar 13
  • Gardasil
  • Fluzone
  • Varivax
  • Cervarix

By geography

  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)

Related Reports:

Cutaneous And Systemic Leishmaniasis Market

Ankle Syndesmosis Treatment Devices Market

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Continue Reading
Editorial & Advertiser disclosure

Recommended